T Dorai

Summary

Affiliation: Columbia University
Country: USA

Publications

  1. ncbi A recombinant defective adenoviral agent expressing anti-bcl-2 ribozyme promotes apoptosis of bcl-2-expressing human prostate cancer cells
    T Dorai
    Molecular Urology Laboratory, Columbia University College of Physicians and Surgeons, New York, NY, USA
    Int J Cancer 82:846-52. 1999
  2. ncbi Therapeutic potential of curcumin in human prostate cancer. II. Curcumin inhibits tyrosine kinase activity of epidermal growth factor receptor and depletes the protein
    T Dorai
    Department of Urology, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
    Mol Urol 4:1-6. 2000
  3. ncbi Therapeutic potential of curcumin in human prostate cancer. III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo
    T Dorai
    Molecular Urology Laboratory, Department of Urology, College of Physicians and Surgeons, Columbia University, New York, New York, USA
    Prostate 47:293-303. 2001

Collaborators

Detail Information

Publications3

  1. ncbi A recombinant defective adenoviral agent expressing anti-bcl-2 ribozyme promotes apoptosis of bcl-2-expressing human prostate cancer cells
    T Dorai
    Molecular Urology Laboratory, Columbia University College of Physicians and Surgeons, New York, NY, USA
    Int J Cancer 82:846-52. 1999
    ..Our results support further development of this adenovirus/anti-bcl-2 ribozyme for potential gene therapeutic purposes in certain forms of hormone-resistant prostate cancer where over-expression of bcl-2 proto-oncogene is indicated...
  2. ncbi Therapeutic potential of curcumin in human prostate cancer. II. Curcumin inhibits tyrosine kinase activity of epidermal growth factor receptor and depletes the protein
    T Dorai
    Department of Urology, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
    Mol Urol 4:1-6. 2000
    ....
  3. ncbi Therapeutic potential of curcumin in human prostate cancer. III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo
    T Dorai
    Molecular Urology Laboratory, Department of Urology, College of Physicians and Surgeons, Columbia University, New York, New York, USA
    Prostate 47:293-303. 2001
    ..To extend these observations made in vitro and to study the efficacy of this potential anti-cancer agent in vivo, the growth of LNCaP cells as heterotopically implanted tumors in nude mice was followed...